The strong phlebotomy reduction and hematocrit control data for DISC-3405 in PV significantly de-risks the program. Traders should watch for the upcoming FDA end-of-Phase 2 meeting for selcodebart and initial sickle cell disease data for DISC-3405, both expected by end of 2026, as key catalysts.
IRON drugs
IRON drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $74.14entry
- T+1 · 2mo ago −5.50%α −6.36% · $70.06
- T+5 · 2mo ago −6.69%α −6.19% · $69.18
- T+20 · 6w ago −18.03%α −20.16% · $60.77
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Disc Medicine presented positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at SOHO 2026, showing significant phlebotomy reduction and hematocrit control. The company also provided an encore of positive Phase 2 RALLY-MF data for selcodebart in anemia of myelofibrosis. Both programs are advancing toward potential pivotal development, with an FDA end-of-Phase 2 meeting for selcodebart expected by year-end.
Key Facts
- DISC-3405 reduced mean total phlebotomy events from 4.0 to 0.6 per 26 weeks (p<0.0001) in PV patients.
- 61.5% of patients remained phlebotomy-free post-baseline through 26 weeks.
- Mean hematocrit maintained stably <45% through week 26.
- DISC-3405 is the first anti-TMPRSS6 mAb to demonstrate phlebotomy reduction in PV patients.
- Disc plans to provide an update on RESTORE-PV and initial Phase 1b data in sickle cell disease by end of 2026.
- Selcodebart (DISC-0974) positive Phase 2 RALLY-MF data encore presented; FDA end-of-Phase 2 meeting expected by year-end.
- PV affects approximately 150,000 patients in the U.S.
Financial Impact
Positive clinical data for two pipeline programs (DISC-3405 in PV, selcodebart in MF) de-risks pivotal development and supports a multi-billion-dollar peak sales opportunity in a large, underserved PV population (~150K U.S. patients). No financial figures provided.
Risk Factors
- DISC-3405 is still in Phase 2; larger pivotal trials are needed to confirm efficacy and safety.
- Competition from existing PV therapies (phlebotomy, cytoreductive agents) and emerging pipeline candidates.
- Selcodebart's FDA end-of-Phase 2 outcome is uncertain; regulatory path for anemia of MF is not established.
- Clinical-stage biotech with no approved products; capital needs for pivotal trials may require future financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359133 |
Track record
43 reports on IRON
7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers